Motor Neuron Disease
Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)
Subtype terms (3)
More specific conditions that are subtypes of Motor Neuron Disease in the MeSH hierarchy.
- Amyotrophic Lateral Sclerosis
291 drugs (123 approved, 168 experimental)
- Bulbar Palsy, Progressive
2 drugs (1 approved, 1 experimental)
- Muscular Atrophy, Spinal
32 drugs (19 approved, 13 experimental)
Drugs by status
Phase 4 trials (1)
Phase 3 trials (2)
Phase 2 trials (14)
Phase 1 trials (9)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (74)
- AB Science
- Eisai
- Cephalon
- Trophos
- MediciNova
- Roche
- Avanir
- Biogen
- Alexion
- Amylyx Pharmaceuticals Inc.
- Brainstorm Cell Therapeutics
- Laboratoire français de Fractionnement et de Biotechnologies
- Knopp Biosciences
- Orphazyme
- Ra Pharmaceuticals
- The Avicena Group
- Collaborative Medicinal Development Pty Limited
- Cytokinetics
- National Institute of Neurological Disorders and Stroke (NINDS)
- Cedars-Sinai Medical Center
- University of London
- Harvard University
- Katholieke Universiteit Leuven
- NHS Lothian
- Okayama University
- Sheffield Hallam University
- Universidad Autonoma de Nuevo Leon
- University of Edinburgh
- University of Kansas
- University of Kentucky
- +44 more
Organization Involved with Phase 2 Indications (145)
- Celgene
- Forest Laboratories
- Astellas
- Gilead Sciences
- Genentech
- Grifols
- Pfizer
- Apotex
- AZTherapies, Inc.
- Novartis
- Allergan
- Corestem, Inc.
- Bioelectron
- Flex Pharma, Inc.
- GlaxoSmithKline
- Implicit Bioscience
- Mallinckrodt
- Merz
- Phoenix Neurological Associates, LTD
- Teva
- Apellis Pharmaceuticals, Inc.
- CytRx
- Genervon Biopharmaceuticals, LLC
- Neuraltus Pharmaceuticals, Inc.
- Q Therapeutics, Inc.
- Stem Cells Arabia
- Center for Neurologic Study, La Jolla, California,
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- IRCCS National Neurological Institute C. Mondino Foundation
- Muscular Dystrophy Association
- +115 more
Organization Involved with Phase 1 Indications (30)
- Chemigen, LLC
- Cognitive Research Corporation
- Ionis Pharmaceuticals, Inc.
- Molecular NeuroImaging
- Red de Terapia Celular
- TCA Cellular Therapy
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- Polish Academy of Sciences
- Shahid Beheshti University of Medical Sciences
- Hospital e Maternidade Dr. Christóvão da Gama
- Rockefeller University
- Medical University of Warsaw
- Royan Institute
- Spanish National Health System
- Universidad de Murcia
- François Rabelais University
- University of Toulouse
- Quotient
- University of Missouri
- Shahed University
- University of Queensland
- University of Perugia
- Clinica Jordy Sinapse
- Public Health Service, Murcia
- Hackensack University Medical Center
- Everfront Biotech Co., Ltd.
- Denali Therapeutics Inc.
- AL-S Pharma
- Rapa Therapeutics LLC
- Band of Hope Foundation
Organization Involved with Other Experimental Indications (15)
- Elysium Health
- University of Roma La Sapienza
- Campus Bio-Medico University
- D'Annunzio University of Chieti–Pescara
- University of Florence
- University of Nebraska
- University of Valencia
- Stony Brook University
- Dalian Medical University
- Zhejiang University
- Cha Medical University
- Cantonal Hospital of St. Gallen
- Avera Health
- Nanjing 1718 Biotech Co. Ltd
- Jiangsu University